Rasmussen S A, Friedman J M
Centers for Disease Control and Prevention, Division of Birth Defects and Developmental Disabilities, Atlanta, GA 30341, USA.
Am J Epidemiol. 2000 Jan 1;151(1):33-40. doi: 10.1093/oxfordjournals.aje.a010118.
Neurofibromatosis 1 (NF1), also known as von Recklinghausen disease, is an autosomal dominant condition caused by mutations of the NF1 gene, which is located at chromosome 17q11.2. NF1 is believed to be completely penetrant, but substantial variability in expression of features occurs. Diagnosis of NF1 is based on established clinical criteria. The presentation of many of the clinical features is age dependent. The average life expectancy of patients with NF1 is probably reduced by 10-15 years, and malignancy is the most common cause of death. The prevalence of clinically diagnosed NF1 ranges from 1/2,000 to 1/5,000 in most population-based studies. A wide variety of NF1 mutations has been found in patients with NF1, but no frequently recurring mutation has been identified. Most studies have not found an obvious relation between particular NF1 mutations and the resulting clinical manifestations. The variability of the NF1 phenotype, even in individuals with the same NF1 gene mutation, suggests that other factors are involved in determining the clinical manifestations, but the nature of these factors has not yet been determined. Laboratory testing for NF1 mutations is difficult. A protein truncation test is commercially available, but its sensitivity, specificity, and predictive value have not been established. No general, population-based molecular studies of NF1 mutations have been performed. At this time, it appears that the benefits of population-based screening for clinical features of NF1 would not outweigh the costs of screening.
神经纤维瘤病1型(NF1),也称为冯雷克林霍增氏病,是一种常染色体显性遗传病,由位于17号染色体q11.2区域的NF1基因突变引起。NF1被认为具有完全的外显率,但在特征表达上存在很大差异。NF1的诊断基于既定的临床标准。许多临床特征的表现取决于年龄。NF1患者的平均预期寿命可能缩短10至15年,恶性肿瘤是最常见的死亡原因。在大多数基于人群的研究中,临床诊断的NF1患病率在1/2000至1/5000之间。在NF1患者中发现了各种各样的NF1突变,但尚未发现常见的复发性突变。大多数研究未发现特定的NF1突变与所产生的临床表现之间存在明显关联。即使在具有相同NF1基因突变的个体中,NF1表型的变异性也表明其他因素参与了临床表现的决定,但这些因素 的性质尚未确定。对NF1突变进行实验室检测很困难。一种蛋白质截短试验已商业化,但尚未确定其敏感性、特异性和预测价值。尚未对NF1突变进行基于人群的全面分子研究。目前,基于人群筛查NF1临床特征的益处似乎不会超过筛查成本。